ArticleMolecular biology reports2025
Interleukin-17 and interleukin-23 cytokine profiles in palindromic rheumatism: potential therapeutic targets and prognostic biomarkers for disease progression to rheumatoid arthritis.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between body mass index and palindromic rheumatism risk and outcomes: a case-control study.Clinical rheumatology · 2026Article
- Comparing clinical outcomes of rheumatoid arthritis by onset type: palindromic rheumatism, undifferentiated arthritis, and typical rheumatoid arthritis.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPalindromic rheumatism (PR) is a rare autoimmune disorder characterized by recurrent inflammatory episodes, often progressing to more severe forms of arthritis, such as rheumatoid arthritis (RA). The interleukin (IL)-17/23 axis plays a crucial role in autoimmunity and joint inflammation; however, its involvement in PR remains unclear. This study aimed to investigate mRNA expression and serum levels of IL-17 and IL-23 in PR, RA, and healthy controls (HCs).
methodsThis cross-sectional study included 20 PR patients, 40 RA patients, and 40 age- and gender-matched HCs. Serum cytokine levels and gene expression were assessed using enzyme-linked immunosorbent assay (ELISA) and real-time polymerase chain reaction (qPCR). Correlations between cytokine levels, joint involvement, and disease activity were analyzed.
resultsSerum and mRNA expression levels of IL-17 and IL-23 were significantly higher in PR and RA patients compared to HCs. Notably, IL-17 and IL-23 levels were significantly higher in PR patients than RA patients, suggesting distinct inflammatory mechanisms. There was a significant positive correlation between IL-17 and IL-23 expression levels in PR and RA groups. However, no significant association was found between cytokine levels with clinical manifestations, autoantibodies and disease activity in PR and RA groups.
conclusionThe research findings provide valuable insights into immune imbalances and increased gene expression and protein levels of IL-17 and IL-23 in PR patients, offering potential therapeutic targets. Targeting these cytokines or their receptors may provide novel therapeutic strategies to prevent PR progression to RA. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
40608144What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.